Program
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905
Also written as “QLS31905” and “QLS31905 for Injection”.
Its studies are mostly in Pancreatic Neoplasms · Biliary Tract Neoplasms · Adenocarcinoma, led by Qilu Pharmaceutical.
Drug pageAnti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 65 open or running | phase 3since Jul 13, 2025 | Feb 23, 2022 | Dec 2026phase 2 · NCT06942767 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 23, 2022First study: phase 1 study in Advanced Solid TumorsFirst studyNCT05278832 · 104 enrolled · China
- Jun 1, 2024Phase 2 study in Advanced Solid TumorNCT06446388 · 360 planned · China
- Apr 17, 2025Phase 2 study in AdenocarcinomaNCT06942767 · 100 planned
- Jul 13, 2025Phase 3 study in Pancreatic NeoplasmsNCT07079228 · 602 planned · China
- Aug 25, 2025Phase 2 study in CLDN18.2-positive Advanced Biliary Tract CancerNCT07151872 · 120 planned
- Jul 16, 2026Phase 3 study in Gastric or Gastroesophageal Junction AdenocarcinomaNCT07716449 · 560 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in AdenocarcinomaNCT06942767
- Sep 2028Primary completion: phase 3 study in Gastric or Gastroesophageal Junction AdenocarcinomaNCT07716449
- Dec 2028Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07079228
TargetBeta
“A bispecific antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18) and the human T-cell surface antigen CD3, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| emaretamigrule | Astellas Pharma | phase 3 | 3 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863 | AstraZeneca | phase 2 | 1 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07716449Gastric or Gastroesophageal Junction Adenocarcinoma · China | 3 | Recruiting | Sep 2028 | 560 |
| NCT07151872CLDN18.2-positive Advanced Biliary Tract Cancer | 2 | Not yet recruiting | Oct 2026 | 120 |
| NCT07079228Pancreatic Neoplasms · China | 3 | Recruiting | Dec 2028 | 602 |
| NCT06942767Adenocarcinoma | 2 | Not yet recruiting | Dec 2026 | 100 |
| NCT06446388Advanced Solid Tumor · China | 2 | Not yet recruiting | Jun 30, 2026 | 360 |
| NCT05278832Advanced Solid Tumors · China | 1 | UNKNOWN | Dec 31, 2022 | 104 |
How it is read
Names in the registry
- “QLS31905”, 4 entries
- “QLS31905 for Injection”, 2 entries
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 1 study
- Biliary Tract Neoplasms, 1 study
- Adenocarcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.